Cargando…
Phase II study of a trastuzumab biosimilar in combination with paclitaxel for HER2-positive recurrent or metastatic urothelial carcinoma: KCSG GU18-18
BACKGROUND: Human epidermal growth factor receptor 2 (HER2) is a widely explored therapeutic target in solid tumors. We evaluated the efficacy and safety of trastuzumab-pkrb, a biosimilar of trastuzumab, in combination with paclitaxel, in HER2-positive recurrent or metastatic urothelial carcinoma (U...
Autores principales: | Kim, M., Lee, J.L., Shin, S.J., Bae, W.K., Lee, H.J., Byun, J.H., Choi, Y.J., Youk, J., Ock, C.Y., Kim, S., Song, H., Park, K.H., Keam, B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485395/ https://www.ncbi.nlm.nih.gov/pubmed/37385153 http://dx.doi.org/10.1016/j.esmoop.2023.101588 |
Ejemplares similares
-
Phase II Study of Dovitinib in Patients with Castration-Resistant Prostate Cancer (KCSG-GU11-05)
por: Choi, Yoon Ji, et al.
Publicado: (2018) -
Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG)
por: Park, H.S., et al.
Publicado: (2021) -
Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/KM10B)
por: Sim, Sung Hoon, et al.
Publicado: (2022) -
Potential role of CMPK1, SLC29A1, and TLE4 polymorphisms in gemcitabine-based chemotherapy in HER2-negative metastatic breast cancer patients: pharmacogenetic study results from the prospective randomized phase II study of eribulin plus gemcitabine versus paclitaxel plus gemcitabine (KCSG-BR-13-11)
por: Cho, E.H., et al.
Publicado: (2021) -
Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12
por: Lee, Yun-Gyoo, et al.
Publicado: (2021)